PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2013.1582014472266-273Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic CancerJae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Chohttp://e-crt.org/upload/pdf/crt-2013-158.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2013.158, http://www.e-crt.org/upload/pdf/crt-2013-158.pdf
Annals of Oncology10.1093/annonc/mdw201.27201627ii92RM-028 Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancerP. Khatri, P. Kumari, S. Beniwal, S. Samdariyahttps://api.elsevier.com/content/article/PII:S0923753419459310?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419459310?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/27/suppl_2/ii92/7509530/mdw201.27.pdf
Annals of Oncology10.1016/s0923-7534(20)33301-9201223ix240A Pilot Trial of Gemcitabine in Combination with Capecitabine or Erlotinib Compared to Gemcitabine alone in Patients with advanced Pancreatic CancerJ.Y. Cho, J.Y. Lim, S.J. Lee, D.K. Lee, J.S. Park, D.S. Yoon, Y.H. Minhttps://api.elsevier.com/content/article/PII:S0923753420333019?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420333019?httpAccept=text/plain
Chemotherapy10.1159/0003439692012585371-380Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological StudyE. Francois, J. Bennouna, E. Chamorey, M.C. Etienne-Grimaldi, N. Renée, H. Senellart, C. Michel, P. Follana, V. Mari, J.Y. Douillard, G. Milanohttps://www.karger.com/Article/Pdf/343969, https://www.karger.com/Article/Pdf/343969, https://www.karger.com/Article/Pdf/343969
European Journal of Cancer Supplements10.1016/s1359-6349(05)81064-x200532219-220769 PUBLICATION Activity and tolerability of combination: capecitabine(c) plus gemcitabine(g) as first-line treatment in patients(pts) with locally advanced/metastatic pancreatic cancerhttps://api.elsevier.com/content/article/PII:S135963490581064X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S135963490581064X?httpAccept=text/plain
European Journal of Cancer Supplements10.1016/s1359-6349(05)81030-4200532209735 POSTER Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancerhttps://api.elsevier.com/content/article/PII:S1359634905810304?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905810304?httpAccept=text/plain
Cancer Chemotherapy and Pharmacology10.1007/s00280-015-2683-12015754683-690Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II studyRoberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, Letizia Laera, Daniele Marrelli, Franco Roviello, Edoardo Francinihttp://link.springer.com/content/pdf/10.1007/s00280-015-2683-1.pdf, http://link.springer.com/article/10.1007/s00280-015-2683-1/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-015-2683-1
Clinical Lung Cancer10.3816/clc.2008.n.037200894235-238An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH TrialCesare Gridelli, Charles Butts, Fortunato Ciardiello, Ronald Feld, Ciro Gallo, Francesco Perronehttps://api.elsevier.com/content/article/PII:S1525730411701681?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411701681?httpAccept=text/plain
European Journal of Cancer Supplements10.1016/s1359-6349(05)82014-220053412PS11 Best of ECCO 13 Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancerhttps://api.elsevier.com/content/article/PII:S1359634905820142?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905820142?httpAccept=text/plain
Annals of Oncology10.1016/s0923-7534(20)30026-0201223iv62P-0108 Docetaxel-Carboplatin for Patients with Advanced Pancreatic Cancer Progressing after Gemcitabine-Based Chemotherapy Followed by Metronomic CapecitabineEhab Shaltout, Eman Abd El Razek, Ahmed El-Gamalhttps://api.elsevier.com/content/article/PII:S0923753420300260?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420300260?httpAccept=text/plain